Adrian Johnson

TLDR: Prosus Ventures is actively searching the Australian market for investment opportunities. They are particularly interested in consumer brands and deep tech startups. The venture arm of Prosus, known for investing in

TLDR: In this article, it discusses the key findings from a recent study on the impact of social media on mental health. The study found that excessive use of social media can

TLDR: Till Rösnick has been promoted to managing director at Wepa Ventures, the CVC arm of German sanitary paper manufacturer Wepa Group. Wepa Ventures focuses on backing and incubating European software-driven material

TLDR: Adriel Chua has joined Alibaba Group as an investment manager to oversee Southeast Asia and Latin America investments. Alibaba has been focusing on AI technology startups and has corporate venture capital

TLDR: Korea’s POBA is renewing its investment strategy to focus on income generation and private credit. They are adopting a barbell approach, with 70-80% allocated to income-generating assets and 20-30% to equity

TLDR: VC-backed startups like Kodama, BurnBot, and Megafire Action are utilizing cutting-edge technology to revolutionize wildfire management and prevention. These companies are racing against time with the support of climate-conscious investors to

TLDR: Code-Create, a HK fashion tech start-up, is partnering with a local VC fund to raise $2 million by 2025 for expansion into mainland China and South Korea. Their AiDA software uses

TLDR: InnoBlock 2024 Airdrop DemoDay event to be held at Singapore Expo from September 16th to 17th, 2024. Over 50 projects expected to participate in on-site roadshow presentations, attracting over 40 leading

TLDR: The success of getting startups plugged into a large corporation lies in designing the investment program strategically. Having clear communication and alignment between the startup and corporate stakeholders is crucial for

Article Summary TLDR: The biopharma sector had the strongest investment quarter in two years Key Points: The second quarter of 2024 had the highest new venture investment in biopharma companies since 2022.